Capital One Financial Comments on Chimerix, Inc.’s Q2 2024 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Equities research analysts at Capital One Financial issued their Q2 2024 earnings per share (EPS) estimates for Chimerix in a research note issued to investors on Wednesday, May 1st. Capital One Financial analyst N. Quibria anticipates that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. Capital One Financial also issued estimates for Chimerix’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at $0.05 EPS, FY2024 earnings at ($0.74) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.62) EPS and FY2027 earnings at ($0.56) EPS.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same period in the previous year, the firm posted ($0.24) earnings per share.

CMRX has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Friday, March 1st. Wedbush reissued an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research note on Monday, February 12th. Finally, StockNews.com cut Chimerix from a “hold” rating to a “sell” rating in a research note on Friday.

Chimerix Trading Up 4.9 %

Shares of CMRX opened at $1.00 on Monday. The business’s 50-day moving average price is $1.04 and its 200 day moving average price is $1.00. The stock has a market capitalization of $89.63 million, a P/E ratio of -1.08 and a beta of 1.13. Chimerix has a 1-year low of $0.88 and a 1-year high of $1.57.

Institutional Investors Weigh In On Chimerix

A number of institutional investors have recently bought and sold shares of CMRX. RA Capital Management L.P. acquired a new stake in Chimerix during the 3rd quarter worth about $6,240,000. Vestal Point Capital LP acquired a new stake in Chimerix during the 4th quarter worth about $1,348,000. Bank of New York Mellon Corp boosted its position in Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares during the period. Assenagon Asset Management S.A. boosted its position in Chimerix by 167.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock worth $410,000 after acquiring an additional 267,044 shares during the period. Finally, Pale Fire Capital SE boosted its position in Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 112,318 shares during the period. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.